Loading...
Loading...
CYT| Name | Value |
|---|---|
| Revenues | 0.0K |
| Cost of Revenue | 100.0K |
| Gross Profit | -100.0K |
| Operating Expense | 9,607.0K |
| Operating I/L | -9,607.0K |
| Other Income/Expense | 1,203.0K |
| Interest Income | 1,203.0K |
| Pretax | -8,404.0K |
| Income Tax Expense | 0.0K |
| Net Income/Loss | -8,404.0K |
Cyteir Therapeutics, Inc. is a clinical-stage biotechnology company specializing in precision oncology medicines. Their lead product, CYT-0851, is a novel, oral, once-daily, small molecule drug candidate currently in Phase I/II clinical trials for monotherapy and combination therapy in solid tumors and hematologic malignancies. Additionally, the company is developing CYT-1853, a preclinical drug for the same indications. By focusing on the development and commercialization of these next-generation precision oncology medicines, Cyteir Therapeutics aims to generate revenue through the successful advancement and eventual commercialization of their drug candidates.
